Blocking P300 HAT activity reverses the epigenetic changes and vascular-like phenotype conversion and reduces tumor growth post-treatment, highlighting its potential as a therapeutic vulnerability for preventing GBM relapse. This evidence concerns the gene TMPRSS11D and glioblastoma.